investors

Press Releases

DateTitle and SummaryView
May 23, 2016
LOS ANGELES , May 23, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday,
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 2, 2016
May 12, 2016
LOS ANGELES , May 12, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced financial results for the first quarter of 2016.  Andrew Gengos , ImmunoCellular Chief Executive Officer, commented: "We continue to make progress in all aspects of
ImmunoCellular Therapeutics Announces First Quarter 2016 Financial Results
May 6, 2016
LOS ANGELES , May 6, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that the Company has received approval from regulatory authorities in Canada , the United Kingdom and the Netherlands to initiate the ICT-107 Phase 3 registration trial
ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma
May 4, 2016
LOS ANGELES , May 4, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2016 financial results on Thursday, May 12, 2016 . The Company also plans to hold a conference call and webcast on that day at 5:00
ImmunoCellular Therapeutics to Report First Quarter 2016 Financial Results on May 12, 2016
March 30, 2016
ICT-107 Phase 3 Registration Trial Underway; Collaborations to Enhance Dendritic Cell and Stem Cell Platform Progressing
ImmunoCellular Therapeutics Announces 2015 Financial Results
March 29, 2016
LOS ANGELES , March 29, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for 2015 on Wednesday, March 30, 2016 . The Company also plans to hold a conference call and webcast on that day at 5:00 pm
ImmunoCellular Therapeutics to Report 2015 Financial Results on March 30, 2016
March 7, 2016
LOS ANGELES , March 7, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the 28 th Annual ROTH Conference on
ImmunoCellular Therapeutics to Present at ROTH Conference on March 16, 2016
February 16, 2016
LOS ANGELES , Feb. 16, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program
February 1, 2016
LOS ANGELES , Feb. 1, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer, will present a corporate overview and business update at the 18 th Annual BIO CEO & Investor Conference at 2:00 pm ET on
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 8, 2016
January 27, 2016
LOS ANGELES , Jan. 27, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced it has entered into a sponsored research agreement with Eduardo Davila , PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School
ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved